Compare Newmont Corporation (NEM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Natera Inc. Common Stock — how do they compare? Newmont Corporation trades at $113.24 (market cap $121.80B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Newmont Corporation is far larger — about 2.1× Natera Inc. Common Stock's market cap, and Newmont Corporation pays a 0.9% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 59 Days and Natera Inc. Common Stock for 0 Days on average.
| NEM | NTRA | |
|---|---|---|
Market Cap | $121.80B | $57.03B |
Volume | 4,383,120 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $425.64 |
52-Week Low | $78.63 | $179.42 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $118.39B | $56.18B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $111.56, down 4.77% over the past 24 hours, with strong fundamental performance including record free cash flow of $5.3 billion in H1 2026 and three consecutive quarterly earnings beats. The stock shows a bullish technical signal with moving averages supporting upward momentum, while maintaining attractive valuation metrics including a P/E of 14.58 and EV/EBITDA of 7.38. Recent news highlights the company's focus on per-share growth and operational improvements amid constructive gold market conditions.
Newmont presents a compelling investment case with robust profitability (33.36% net margin), strong analyst consensus (76% buy ratings), and 22% upside to the $136.83 price target. Key risks include gold price volatility and execution of growth initiatives, but the company's record cash flow generation and improving balance sheet provide solid foundation for continued shareholder value creation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
